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Abstract
Using a differential display method to identify differentiation-related genes in human myelomonocytic U937 cells, we
cloned the cDNA of a gene identical to Drg1 and homologous to other recently discovered genes, respectively human RTP
and Cap43 and mouse Ndr1 and TDD5 genes. Their open reading frames encode proteins highly conserved between mouse
and man but which do not share homology with other know proteins. Conditions in which mRNAs are up-regulated suggest
a role for the protein in cell growth arrest and terminal differentiation. We raised antibodies against a synthetic peptide
reproducing a characteristic sequence of the putative polypeptide chain. These antibodies revealed a protein with the
expected 43 kDa molecular mass, up-regulated by phorbol ester, retinoids and 1,25-(OH)2 vitamin D3 in U937 cells. It was
increased in mammary carcinoma MCF-7 cells treated by retinoids and by the anti-estrogen ICI 182,780 but not by
4-hydroxytamoxifen. The mouse Drg1 homologous protein was up-regulated by retinoic acid in C2 myogenic cells. The
diversity of situations in which expression of RTP/Drg1/Ndr1 has now been observed shows that it is widely distributed and
up-regulated by various agents. Here we show that ligands of nuclear transcription factors involved in cell differentiation are
among the inducers of this novel protein. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The progression of cells towards terminal di¡eren-
tiation requires the concerted expression of numer-
ous speci¢c genes. Established cell lines allow to re-
produce in vitro some aspects of this process and
provide experimental models to investigate the mo-
lecular mechanisms through which transformed cells
recover the phenotype of their normally di¡erenti-
ated counterparts. Human leukemic U937 cells cease
to proliferate and express functional properties upon
treatment with 1,25-(OH)2 vitamin D3 (VD) or reti-
noic acid (RA). We have previously shown that these
agents and their derivatives act synergistically to in-
duce the macrophagic di¡erentiation of U937 cells,
the highest e¡ect being achieved with combinations
of VDR, RXR and RAR agonists ([1] and references
therein). We used a strategy based on the di¡erential
display technique of Liang and Pardee [2] to identify
novel genes expressed in di¡erentiating U937 cells.
Among a collection of di¡erentially expressed frag-
ments of cDNA, we focused our attention on a
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strongly induced cDNA which proved to be identical
to Drg1, recently cloned in colon epithelial cells [3]
and, with one nucleotide di¡erence, similar to RTP
and Cap43, discovered by di¡erential display in other
experimental models [4,5]. Comparison of the poten-
tial mouse and human open reading frames indicates
a protein highly conserved between mammalian spe-
cies. However, these sequences do not reveal any
homology with other known proteins, susceptible to
give indications on the role of the protein in cell
physiology. The fact that its mRNA is up-regulated
under conditions where cells cease to proliferate sug-
gests a role for the protein in cells undergoing termi-
nal di¡erentiation. In order to study RTP/Drg1/Ndr1
expression at the protein level, we raised antibodies
against a repeated sequence characteristic of the pu-
tative polypeptide chain. Western blot analyses re-
vealed a 43 kDa protein, consistent with the pre-
dicted open reading frame, which actually displayed
increased expression in various models of human and
mouse cells induced to growth arrest and di¡erentia-
tion.
2. Materials and methods
2.1. Cell lines
The U937 (myelomonocytic cell line, human; cell
culture conditions described in [1]), Jurkat (leukemic-
T cell line, human; cell culture conditions described
in [6]) and MCF-7 (mammary carcinoma cell line,
human; cell culture conditions described in [7])
were purchased from ATCC (Rockville, MD,
USA). Mouse C2 myogenic cells and the C2-R sub-
clone were a generous gift from Dr. A. Bonnieu (cell
culture conditions described in [8]).
2.2. mRNA di¡erential display and multiplex
messenger assay
Total RNA extracted from U937 cells with Trizol
(Gibco BRL, Life Technologies, Gaithersburg, MD,
USA) and cleaned up with DNase I was used for
reverse transcription with Superscript II reverse tran-
scriptase (Gibco BRL). For di¡erential display, PCR
reactions were performed using RNA Image follow-
ing manufacturer’s instructions (GenHunter, Nash-
ville, TN, USA), with random 30-mers and anchored
primers. Ampli¢ed cDNA fragments, labeled by in-
corporation of [K-32P]dCTP, were separated on 6%
polyacrylamide gels. Following electrophoresis, the
gels were layered on pieces of 3M paper without
drying and radioactivity measured using a Storm An-
alyser (Molecular Dynamics, Sunnyvale, CA, USA).
The bands of interest were cut from the gel, eluted
and re-ampli¢ed using the same PCR conditions.
Each selected cDNA fragment was cloned into a
pCR-TRAP vector (GenHunter) according to manu-
facturer’s instructions. Plasmids were extracted with
the Qiagen Plasmid Mini Kit (Qiagen, Courteboeuf,
France). The plasmids were dissolved in water,
boiled for 10 min, and cooled. Three di¡erent
amounts of each plasmid in 2Ustandard saline cit-
rate (SSC), respectively 75, 150 and 300 ng, were
spotted in duplicate on Hybond-N nylon membranes
(Amersham Life Science, Buckinghamshire, UK)
brie£y wetted in 2USSC. Dot blotting was per-
formed using a Bio-Rad manifold (Bio-Rad, Ivry,
France). Following application of the plasmids,
membranes were rinsed twice with 500 Wl of
2USSC, removed from the manifold and dried for
1 h at 80‡C in a vacuum oven. Filters were prehy-
bridized for 4 h with 50% formamide, 5USSPE, 5U
Denhardt, 1% SDS, 20 Wg/ml salmon sperm DNA
and 5% dextran at 42‡C. Two probes were prepared,
starting from 5 Wg of total RNA extracted respec-
tively from proliferating and 4 h di¡erentiated
U937 cells. The samples were dissolved in 12 Wl
DEPC-treated H2O with 1 Wl of oligo(dT12ÿ18) (500
Wg/ml), heated for 10 min at 70‡C and quickly chilled
on ice. After a brief centrifugation, 1 Wl of (dATP,
dGTP and dTTP (25 WM each), dCTP (0.25 WM)),
2 Wl of DTT (0.1 M) and 5 Wl of [K-32P]dCTP (6000
Ci/mmol) were added and the mixture incubated for
2 min at 42‡C. Superscript II reverse transcriptase
(Gibco BRL) was then added and the reaction per-
formed for 1 h at 42‡C. The radioactive cDNA was
isolated by ¢ltration through a Sephadex G-25 col-
umn eluted with Tris 50 mM, LiCl 0.4 M. A sample
containing 10 million cpm was boiled for 10 min,
chilled on ice and added to the prehybridization mix-
ture. Hybridization was performed overnight, and
membranes washed in 0.2USSC at 60‡C. The
amounts of radioactivity retained on ¢lters were
evaluated using a Storm Phosphor Imager (Molecu-
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lar Dynamics). Spots were visualized and the radio-
activity was quanti¢ed using the Storm Imager soft-
ware. Standardization was based on the signal given
by L2-microglobulin mRNA.
2.3. 5P-RACE
Total RNA was extracted with Trizol (Gibco BRL
Life Technologies). The 5P-RACE reaction was per-
formed using 5P-RACE for Rapid Ampli¢cation of
cDNA Ends, version 2.0 according to the manufac-
turer’s protocol (Gibco BRL). The primers were as
follows: for the ¢rst strand cDNA synthesis: 5P-
TAA-GAA-ACT-CCT-CTG-G-3P and for PCR: 5P-
AGT-CAT-TGC-CTC-TCA-CG-3P.
2.4. Northern blot analyses
Total RNAs extracted from cultured cells were
separated by electrophoresis in 1% agarose/formalde-
hyde denaturing gel and transferred onto nylon
membranes (Hybond-N, Amersham). cDNA probes
were labeled with [32P]dCTP using a random priming
kit (Boehringer Mannheim). Hybridization was per-
formed at 42‡C in 50% formamide, and membrane
washes were done in 0.2USSC (60‡C). The amounts
of probe retained on ¢lters were measured in situ
using a Storm Phosphor Imager (Molecular Dynam-
ics).
2.5. Immunological detection of the Drg1 protein
Rabbit polyclonal antisera were raised against
(EGTRSRSHTS)2. Synthesis of the peptide and rab-
bit immunizations was performed by AGRO-BIO
(Villeny, France). For Western blotting, cells were
lysed in 4Usample bu¡er (10% Tris 1 M pH 6.8,
30% SDS 20%, 30% glycerol, 30% L-mercaptoetha-
nol). Cell extracts (each corresponding to 100 000
cells/lane) were fractionated by SDS-PAGE on a
10% polyacrylamide gel and blotted onto nitrocellu-
lose ¢lters using a semi-dry electroblotter (Millipore,
St Quentin en Yvelines, France) at 0.8 mA/cm2 for
1 h. The nitrocellulose ¢lters were then blocked with
5% non-fat powdered milk in PBS and incubated
with the antisera diluted in PBS. The ¢lters were
probed with mouse peroxidase labeled protein A
and the speci¢c complexes were revealed by ECL-
photochemiluminescence according to the manufac-
turer’s protocol (Amersham, Les Ullis, France). For
detection of Drg1 by immuno£uorescence, cells were
¢xed in cold methanol for 2 min and permeabilized
with 0.1% Triton X-100 in PBS for 5 min. Cells were
incubated with AB human serum (HS) for 10 min,
washed with PBS, incubated for 2 h with anti-Drg1
polyclonal antibodies (1/250 dilution in PBS with 1%
HS), washed twice, incubated with rhodamine goat
anti-rabbit antibody for 1 h and rinsed twice in PBS.
Fluorescence was observed with a Leica confocal
microscope. For £ow cytometry analyses, cells were
¢xed in suspension with 1% paraformaldehyde in
PBS/Tween 0.01% v/w for 2 h and permeabilized
with PBS/Tween 0.5%/BSA 2% for 10 min. Cells
were preincubated for 10 min with HS, for 1 h
with rabbit polyclonal antibodies, washed 3 times,
incubated for 30 min with £uorescein-conjugated sec-
ondary antibody and washed 3 times in PBS. Cell
£uorescence intensity was measured using a FACS-
Calibur analyzer (Becton Dickinson) and data proc-
essed using manufacturer’s programs.
3. Results
3.1. Detection and characterization of Drg1 in U937
cells by mRNA di¡erential display analysis
We used a mRNA di¡erential display assay to
compare gene expression in proliferating U937 cells
and in cells treated for 4 h with VD associated with a
combination of RAR and RXR agonists, respectively
TTNPB and LGD1069 [1]. In a series of experiments
using di¡erent combinations of primers, about 1500
bands were visualized on gel autoradiograms and 42
of them were found to display signi¢cant variations.
The corresponding cDNA fragments were eluted,
cloned and spotted on ¢lters for multiplex messenger
assay (MMA) [9]. Data were further re-evaluated by
Northern blotting [10]. Fig. 1 shows the visual pat-
terns (A,C) and quantitative data (B) for several
clones, selected to illustrate the various situations
encountered in this analysis.
Interestingly, clone 26 was strongly up-regulated
during U937 cell di¡erentiation, as con¢rmed by
MMA and Northern blot (Fig. 1). Sequencing of
this cDNA fragment (303 bp) and computer data-
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base search indicated 100% homology to the di¡er-
entiation-related gene (Drg1) cDNA, previously re-
ported by van Belzen et al. [3]. 5P-RACE allowed
to obtain the full coding sequence (1184 bp), con-
¢rming that the cDNA identi¢ed in U937 was iden-
tical to Drg1 (GenBank accession No. X92845) and,
with one amino acid di¡erence, homologous to the
two human genes RTP (99.5% homology; GenBank
accession No. D87953) and Cap43 (99.5% homology;
GenBank accession No. AF004162). These genes are
homologous to two Mus musculus genes, respectively
Ndr1 (83.5% homology; GenBank accession No.
U60593) and TDD5 (82.5% homology; GenBank ac-
cession No. U52073). Sequence alignments are given
elsewhere [5]. The mammalian genes are slightly ho-
mologous to the Caenorhabditis elegans gene
ZK1073.1 (29% homology; GenBank accession No.
Z68135).
3.2. Immunological characterization of the putative
Drg1 protein
The open reading frame predicts a 394 amino acid
peptide chain, with a deduced molecular mass of 43
kDa. Computer database searches using a variety of
programs available on the Infobiogen site (http://in-
fobiogen.fr) have not until now revealed signi¢cant
consensus motifs susceptible to give indications
about its biological function, except for a possible
phosphopantethein attachment site identi¢ed with
PROSITE (http://genebio.com/prosite.html). The
most prominent feature is a novel highly hydrophilic
ten amino acid unit tandemly repeated three times
near the C-terminus.
Since this sequence was susceptible to provide an
epitope for the immunological detection of the pro-
tein, we selected within it a ten amino acid tandem
repeat, allowing to design a 20-mer synthetic peptide
which was used as immunogen. This sequence is
present in the human RTP, Drg1, Cap43 and, with
minor di¡erences, in the mouse Ndr1 and TDD5
proteins (Fig. 2). High titer rabbit polyclonal anti-
bodies were obtained, recognizing one band with the
expected 43 kDa molecular mass (Fig. 3A) in West-
ern blot assays of U937 cell extracts: an ECL signal
was recorded in less than 1 min using a 5000-fold
dilution of the antiserum sampled on day 53 after
the ¢rst injection and two booster injections. No sig-
nal was observed with the preimmune rabbit serum.
The speci¢city of the antibodies was con¢rmed by
depletion experiments, using antisera preincubated
with the peptide used for immunization (Fig. 3A).
Speci¢c signals were also observed by £uorescence
microscopy in the cytoplasm of di¡erentiated U937
cells (Fig. 3B) and by analytical £ow cytometry of
Fig. 1. Multiplex messenger assay and Northern blot analyses.
(A) 75, 150 and 300 ng of plasmids were dotted in duplicate
sets onto nylon membranes and hybridized with 32P labeled
cDNA prepared by reverse transcription of mRNAs extracted
respectively from proliferating U937 cells (untreated cells) and
from U937 incubated for 4 h with 1,25-dihydroxy vitamin D3
(100 nM), TTNPB (100 nM) and LGD1069 (1 WM) (treated
cells). A human L2-microglobulin (L2m) probe, cloned in a
pCR-TRAP vector, was used for quantitative calibration. (B)
Comparison of intensity values after hybridization of ¢lters de-
scribed in A. (C) Northern blots were carried out with 30 Wg of
total RNA from untreated or treated cells as indicated and hy-
bridized with 32P labeled plasmids as indicated.
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Fig. 2. Nucleotide and amino acid sequence alignment near the C-terminus part of RTP/Drg1/Cap43 human gene, and mouse TDD5
and Ndr1 genes, showing the highly hydrophilic region formed by ten amino acid units tandemly repeated three times (gray boxes).
The 20-mer synthetic peptide, which was used as immunogen, is underlined. Amino acids that are identical to those in the Drg1 se-
quence, are shown as dashes.
Fig. 3. Characterization of Drg1 in U973 cells. U973 cells were cultured at di¡erent times in the absence (NT) or presence of VD
(100 nM), TTNPB (100 nM) and LGD1069 (1 WM). (A) Time course of Drg1 induction in U973 cells. Western blot was revealed by
ECL with anti-Drg1 antibodies. The speci¢city of the band was checked by depletion experiment using polyclonal antibodies against
RTP/Drg1/Ndr1 preincubated with the peptide used for immunization and using non-immune rabbit serum. Marker size is indicated
in kilodaltons. (B) Confocal microscopy analysis of Drg1 expression. U937 cells were cultured for 48 h with di¡erentiation inducers as
in A. Fixed cells were stained with anti-Drg1 antibodies and revealed by rhodamine conjugated goat anti-rabbit F(ab)P2. Controls
were achieved using antibodies preincubated with the peptide used for immunization and using non-immune rabbit serum. (C) Expres-
sion of Drg1 analyzed by £ow cytometry. U937 cells were cultured for 48 h with di¡erentiation inducers and stained by indirect im-
muno£uorescence with anti-Drg1 antibodies (black line). Controls were achieved using antibodies preincubated with the peptide used
for immunization (gray line) and using non-immune rabbit IgG (black line, ¢lled histogram).
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permeabilized cells (Fig. 3C). Increased expression of
the Drg1 protein was observed in U937 cells treated
with VD and the synthetic retinoids TTNPB and
LGD1069 (Fig. 3A), under conditions where an in-
creased expression of Drg1 mRNA was originally
detected by di¡erential display and further con¢rmed
by Northern blot analysis (Fig. 1C).
3.3. Expression of the RTP/Drg1/Ndr1 protein during
cell growth arrest and di¡erentiation
We ¢rst investigated the e¡ects of retinoids (RA or
RAR synthetic agonists) on U937 cells and other cell
types. The proliferation of U937 cells is inhibited to
some extent and cells express some monocyte-macro-
phage functions following treatments with RA. Ret-
inoids also inhibit the estradiol-induced proliferation
of human MCF-7 mammary carcinoma cells [11,12].
In the case of C2 myoblasts, retinoids are e⁄cient
inducers of both growth arrest and di¡erentiation
[8]. In all these cases, we found an increased expres-
sion of a 43 kDa protein revealed by anti-Drg1 anti-
bodies (Figs. 3^5).
Studies with other inducers or cell culture condi-
tions revealed more complex patterns. VD, an in-
ducer of monocytic di¡erentiation with some e¡ects
on U937 cell growth inhibition, was able to induce
the expression of Drg1. TGF-L1, which strongly po-
tentiates the e¡ects of VD on U937 cell growth in-
hibition and monocytic di¡erentiation [13], had no
signi¢cant e¡ect on Drg1 expression either alone or
in combination with VD (Fig. 4A). Conversely, ret-
inoids, which also synergize with VD to induce cell
growth inhibition and di¡erentiation of U937 cells
[1], co-operated with VD to stimulate Drg1 expres-
sion (Fig. 4A). Phorbol myristate acetate (PMA),
which exerts a potent e¡ect on growth arrest and
monocyte-macrophage di¡erentiation of U937 cells,
was found to up-regulate the protein (Fig. 4A). A
positive e¡ect of PMA was also detected in mouse
macrophagic J774 cells (Fig. 4B).
Myogenic C2-R cells have been characterized as
C2 subclones resistant to growth inhibition and dif-
ferentiation by RA [8]. These cells can be di¡erenti-
ated by incubation in a poorly mitogenic medium
(1% FCS) containing insulin (1 WM). After 3 days
of incubation, they express myogenin, a muscle spe-
ci¢c marker of terminal di¡erentiation, at a level
similar to that observed in the parental RA-di¡er-
entiated C2 cells (Fig. 4C). We observed that prolif-
erating C2-R cells did not express the RTP/Drg1/
Ndr1 protein. Upon di¡erentiation in insulin-con-
taining medium, they expressed a low level of RTP/
Drg1/Ndr1 but we found that the presence of RA
had no e¡ect on this expression. The level of RTP/
Drg1/Ndr1 remained very low, contrasting with the
high level observed in the parental cell line (Fig. 4C).
To get a further insight into the e¡ects of lipo-
philic agents on RTP/Drg1/Ndr1, we studied its ex-
pression in human mammary carcinoma MCF-7
cells. The growth of MCF-7 is estrogen-dependent.
Cells cease to proliferate and accumulate in the G1
phase of the cell cycle when suppressing estrogen
stimulation [11,12]. We found that the basal level
of RTP/Drg1/Ndr1 protein, observed in proliferating
cells cultured in the presence of 1 WM estradiol (E2),
was not increased when removing E2 from the cul-
ture medium (Fig. 5A). In E2-stimulated cells, the
RAR-speci¢c agonist TTNPB (10 nM) or the pure
anti-estrogen ICI 182,780 (10 nM) failed to increase
the protein level. At the same concentration, but in
the absence of E2, both agents stimulated its expres-
Fig. 4. Immunologic detection of RTP/Drg1/Ndr1 protein dur-
ing cell di¡erentiation. Cells were cultured for 48 h (except for
C2 and C2-R, cultured for 72 h) with di¡erent combinations of
VD, RA, TTNPB (100 nM each), LGD1069 (1 WM), insulin (1
WM) and PMA (100 ng/ml). Western blots were revealed by
ECL with anti-Drg1 antibodies. (C) Myogenin was immunola-
beled with mouse anti-myogenin antiserum.
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sion (Fig. 5A). In cell cultures run in parallel, in the
absence of E2, the RXR-speci¢c agonist LGD1069
and the partial anti-estrogen 4-hydroxytamoxifen
(OH-TAM) had no signi¢cant e¡ect on RTP/Drg1/
Ndr1 protein expression and we did not detect co-
operative e¡ects between the RAR and RXR ago-
nists (Fig. 5A).
Extending our investigations to other cell lines, we
detected a basal expression of RTP/Drg1/Ndr1 in
proliferating human leukemic Jurkat T-cells (Fig.
5B). We used forskolin (100 WM) ([6] and references
therein) to inhibit Jurkat cell growth (respectively
40% inhibition after 24 h and 65% after 48 h) with-
out detectable apoptosis, as assessed by the absence
of annexin V at the cell surface (data not shown).
This cell growth inhibition was not associated with
an increased expression of the RTP/Drg1/Ndr1 pro-
tein (Fig. 5B).
4. Discussion
The emergence of new technologies for studying
simultaneously the expression of large numbers of
genes, together with the determination of a growing
number of partial cDNA sequences (expressed se-
quence tags, EST), now allows to identify numerous
novel genes in mouse and human species. RTP, [4],
Drg1 [3] and Cap43 [5] refer to genes the products of
which were independently found by mRNA di¡eren-
tial display in various human cells and tissues. A
cDNA clone (rit42) identical to RTP was identi¢ed
using a di¡erential screening technique, on the basis
of its reduced expression in tumor cells [14]. In the
present work, the inducible expression of Drg1 was
again observed in a mRNA di¡erential display ex-
periment. The predicted human protein sequences
di¡er by only one amino acid and the minor di¡er-
ences between the nucleotide sequences do not allow
to ascertain the existence of more than one gene in
the human genome. In fact, the di¡erences between
human sequences might re£ect allelic variations. A
murine homologous gene, Ndr1, has been identi¢ed
[15]. The mouse TDD5 predicted protein [16] di¡ers
signi¢cantly from other proteins in the C-terminal
region and might thus represent another member of
this family. In our work, the complete cDNA se-
quence was determined only in the case of U937
cells, indicating the product of a gene identical to
Drg1. We thus used this term to name the protein
revealed in this cell line and we tentatively used the
generic term RTP/Drg1/Ndr1 to name the protein
revealed in other cell types. A more accurate nomen-
clature awaits further progress in the characterization
of this novel gene and protein family.
Until now, it has not been possible to ¢nd signi¢-
cant homologies between the predicted RTP/Drg1/
Ndr1 proteins and any protein with a known func-
tion. A ¢rst step in understanding its biological role
is to determine when and where this novel gene is
expressed. The UniGene collection (http://
www.ncbi.nlm.nih.gov/UniGene/) provides a non-re-
dundant set of clusters, each one containing sequen-
ces that represent a unique gene or highly related
genes. A recent UniGene release (No. 55, 8 October
1998) indicates that the cluster de¢ned by RTP, Drg1
and Cap 43 (Hs 75789) also contains the sequences of
184 ESTs representing cDNA fragments and thus
mRNAs originating from a wide variety of human
tissues. The cluster containing the mouse Ndr1 and
TDD5 sequences (Mm 4063) contains 70 ESTs se-
Fig. 5. Immunologic detection of RTP/Drg1/Ndr1 protein dur-
ing cell growth arrest. MCF-7 cells were cultured for 48 h and
Jurkat cells during di¡erent times, with di¡erent combinations
of (A) E2 (1 WM), TTNPB (100 nM), LGD1069 (30 nM), ICI
182,780 (10 nM), OH-TAM (10 nM) or (B) forskolin (100
mM). Western blots of cells during cell growth arrest were la-
beled with anti-Drg1 antibodies and revealed by ECL. In B via-
ble cells (s 95%) were counted after staining with trypan blue.
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quences representing mRNAs extracted from brain,
embryo, kidney, macrophage, mammary gland,
muscle, skin, thymus and uterus. These data show
that, at least at the transcriptional level, RTP/Drg1/
Ndr1 expression is not tissue-speci¢c.
In the present work, we prepared antibodies to
study RTP/Drg1/Ndr1 expression at the protein level.
We raised these antibodies against a repeated motif,
which is unique to the putative proteins. RTP and
Cap 43 have the same predicted peptide sequence
and can be distinguished only by a few di¡erences
in the 3P-untranslated region of their mRNAs. Drg1
di¡ers from the four other sequences by one amino
acid (threonine instead of isoleucine) because of a T-
to-C transition but this di¡erence is not localized in
the chosen epitope. The TDD5 predicted sequence
contains two ten amino acid repeats which match
with the synthetic peptidic antigen. Ndr1 has the
three characteristic tandem repeats, and the two ami-
no acid changes by which they di¡er from the human
sequence are substitutions to similar residues. There-
fore, we expected the antibodies to recognize all the
predicted proteins. In all cell extracts, either human
or murine, where a positive reaction was registered, a
unique band was observed in Western blot with the
expected apparent molecular mass (43 kDa). In dif-
ferentiated U937 cells, cell labeling showed strong
cytoplasmic staining, as observed in di¡erentiated
colon carcinoma cells [3]. The diversity of cell types
in which we observed a positive band in Western blot
experiments con¢rmed, at the protein level, the lack
of tissue speci¢city and widespread occurrence of
RTP/Drg1/Ndr1 gene products previously seen by
others at the mRNA level (Table 1). These studies
also con¢rmed that the level of expression of RTP/
Drg1/Ndr1 is highly variable depending on cell type
and culture conditions, thus accounting for the reit-
erated discovery of its transcription products by sev-
eral groups of investigators using di¡erential screen-
ing techniques. The emerging picture is that RTP/
Drg1/Ndr1 is a widely expressed gene, coding for a
cytoplasmic protein, which may be translocated in
the nucleus [3,14], which seems to be down-regulated
in tumor cells and up-regulated in cells which di¡er-
entiate and cease to proliferate. This regulation is
complex and di¡erent cases must be considered. (i)
The protein may be present but not up-regulated
upon cell growth arrest. Removing estradiol from
the culture medium of MCF-7 cells or treating Jurkat
T-cells with forskolin did not increase the basal ex-
pression observed in proliferating cells. A lack of
Drg1 induction in cells which cease to proliferate
was also reported in A431 epidermoid carcinoma
cells [3]. These data suggest that the signals triggering
RTP/Drg1/Ndr1 induction may not depend merely
on cell cycle arrest. (ii) Inductions of RTP, Drg1,
Cap43 and rit42 have been observed upon treatments
involving some forms of cellular stress (respectively
exposure to reducing agents or tunicamycin, glucose
starvation, nickel compounds, DNA damaging
agents). In HUVEC, RTP mRNA was induced in
parallel with the mRNA of GRP78/BiP, a molecular
chaperone up-regulated by the same toxic agents [4].
More recently, up-regulation of RTP/rit42 was found
closely associated with p53 expression [14]. In normal
colon, Drg1 is expressed at the terminal stage of
di¡erentiation, just preceding apoptosis and shedding
of cells in the colon lumen [3]. Induction of RTP/
Table 1
Cell types and treatments in which RTP/Drg1/Ndr1 gene expression was found to be up-regulated
Cell type RTP/Drg1/Ndr1 expression inducers
Endothelial cells [4,20] (HUVEC) Homocysteine, 2L-mercaptoethanol, Tunicamycin, lysophosphatidylcholine
Colon carcinoma cell [3] (HT29-D4, Caco-2) Decreased glucose concentration
Pulmonary epithelial cells [5] (A549, HTE, Calu-1) NiCl2, Ni3S2
Lung ¢broblasts [5] (WL-38) NiCl2, Ni3S2
Osteosarcoma [5] (HOS) NiCl2, Ni3S2
Null-p53 cell lines [14] p53, DNA-damaging agents
Myelomonocytic cells (U937) Retinoids, vitamin D, PMA
Macrophagic cells (J774) (mouse cells) PMA
Mammary carcinoma cells (MCF-7) Anti-estrogen ICI 182,780, RAR agonist TTNPB
Myoblast cells RA sensitive (C2) (mouse cells) Retinoic acid
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Drg1/Ndr1 might thus be linked to cellular stress,
terminal di¡erentiation leading to senescence and
cessation of proliferation preceding apoptosis. (iii)
The wide cellular distribution of RTP/Drg1/Ndr1
transcripts suggests that their expression depends
on diverse stimuli. Here, we report the induction of
RTP/Drg1/Ndr1 by VD and retinoids, agents known
to play biological roles in the development of em-
bryos and in the control of tissue homeostasis in
the adult. Van Belzen et al. also described a retinoic
acid induction of Drg1 expression [17]. The pleio-
tropic e¡ects of retinoids, VD and other lipophilic
signals on cell growth and di¡erentiation are medi-
ated by nuclear receptors (RARs and RXRs and
VDR) which belong to the superfamily of ligand in-
ducible transcription factors. A characteristic feature
of this family of receptors is that they act as hetero-
dimers, in which RXRs play a central role since they
form heterodimers with the other nuclear receptors,
including RARs and the VD receptor [18,19]. De-
pending on the cellular context, the RXR receptor
may or may not be itself ligand activatable by spe-
ci¢c retinoids. These interactions o¡er multiple pos-
sibilities of cross-talk between lipophilic endocrine
signals, so that each cell type exhibits its own pattern
of reactivities. In the present work, we have studied
the expression of the protein in three well-established
experimental cell models. In U937 cells, where the
di¡erentiation induced by VD is potentiated by
RXR and RAR-speci¢c ligands [1], the extent of in-
duction of Drg1 was in agreement with the potency
of combinations of di¡erentiation inducers. Drg1
was induced both by VD and RA alone, but the
highest protein level was found in cells treated by a
combination of VD, RAR and RXR agonists previ-
ously shown to give optimal e¡ects on di¡erentia-
tion, leading to cells which are not apoptotic at
this stage and which express multiple macrophage-
speci¢c functions ([1] and references therein). The
strong and early (4 h) induction of mRNA, which
originally justi¢ed the selection of Drg1 in our
mRNA di¡erential display experiment, shows that
a major regulation occurs at the transcriptional level.
An induction in response to RAR-, but not RXR-
speci¢c retinoids was also observed in MCF-7 cells.
In this case, we found that RTP/Drg1/Ndr1 expres-
sion was also controlled by molecules having a pure
anti-estrogenic e¡ect (ICI 182,780), but not by other
anti-estrogens (OH-TAM), suggesting a complex net-
work of interactions at the level of ligand-activatable
nuclear transcription factors. The sensitivity to RA
was also illustrated by the very di¡erent behavior of
myogenic C2 and C2-R cells, the conspicuous expres-
sion of the protein in RA-sensitive cells contrasting
with its very low expression in RA-resistant cells
brought to the same stage of muscle di¡erentiation.
It will thus be interesting to investigate the structure
of the Drg1 promoter looking for responsive ele-
ments characteristic of the VDR/RAR/RXR family.
At present, nothing is known on the biological role
of RTP/Drg1/Ndr1. However, it seems clear that it is
associated with, and probably plays itself a role [14]
in a cellular mechanism involving the loss of prolif-
erative potential.
Acknowledgements
This work was supported by the Institut National
de la Sante¤ et de la Recherche Me¤dicale, the Ligue
Nationale Contre le Cancer and the Association pour
la Recherche contre le Cancer. We thank Se¤verine
Alric, Dr A. Bonnieu, Dr Anne Froeschle¤ and Dr
J.C. Nicolas for useful discussions.
References
[1] H. Defacque, C. Sevilla, D. Piquemal, C. Rochette-Egly, J.
Marti, T. Commes, Leukemia 11 (1997) 221^227.
[2] P. Liang, A.B. Pardee, Science 257 (1992) 967^971.
[3] N. van Belzen, W.N. Dinjens, M.P. Diesveld, N.A. Groen,
A.C. van der Made, Y. Nozawa, R. Vlietstra, J. Trapman,
F.T. Bosman, Lab. Invest. 77 (1997) 85^92.
[4] K. Kokame, H. Kata, T. Miyata, J. Biol. Chem. 271 (1996)
29659^29665.
[5] D. Zhou, K. Salnikow, M. Costa, Cancer Res. 58 (1998)
2182^2189.
[6] S. Erdogan, M.D. Houslay, Biochem. J. 321 (1997) 165^
175.
[7] E. Demirpence, P. Balaguer, F. Trousse, J.C. Nicolas, M.
Pons, D. Gagne, Toxicol. Appl. Pharmacol. 145 (1997) 111^
123.
[8] A. Froeschle¤, G. Carnac, S. Alric, D. Montarras, C. Pinset,
C. Rochette-Egly, A. Bonnieu, Oncogene 12 (1996) 411^421.
[9] C. Nguyen, D. Rocha, S. Granjeaud, M. Baldit, K. Bernard,
P. Naquet, B.R. Jordan, Genomics 29 (1995) 207^216.
[10] P. Liang, A.B. Pardee, Curr. Opin. Immunol. 7 (1995) 274^
280.
BBAMCR 14484 29-6-99
D. Piquemal et al. / Biochimica et Biophysica Acta 1450 (1999) 364^373372
[11] N.R. Wilcken, B. Sarcevic, E.A. Musgrove, R.L. Sutherland,
Cell Growth Di¡er. 7 (1996) 65^74.
[12] N.R. Wilcken, E.A. Musgrove, R.L. Sutherland, Int. J. Can-
cer 70 (1997) 291^296.
[13] H. Defacque, D. Piquemal, A. Basset, J. Marti, T. Commes,
J. Cell. Physiol. 178 (1999) 109^119.
[14] S.K. Kurdistani, P. Arizti, C.L. Reimer, M.M. Sugrue, S.A.
Aaronson, S.W. et ee, Cancer Res. 58 (1998) 4439^4444.
[15] Unpublished work. GenBank accession No. U60593.
[16] T. Lin, C. Chang, Biochemistry 94 (1997) 4988^4993.
[17] N. van Belzen, W.N. Dinjens, B.H. Eussen, F.T. Bosman,
Histol. Histopathol. 13 (1998) 1233^1242.
[18] C.K. Glass, Endocr. Rev. 15 (1994) 391^407.
[19] D.J. Mangelsdorf, R.M. Evans, Cell 83 (1995) 841^845.
[20] N. Sato, K. Kokame, K. Shimokado, H. Kato, T. Miyata,
J. Biochem. 123 (1998) 1119^1126.
BBAMCR 14484 29-6-99
D. Piquemal et al. / Biochimica et Biophysica Acta 1450 (1999) 364^373 373
